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Abstract: The gut-derived incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are secreted after meal ingestion and work in concert to promote
postprandial insulin secretion. Furthermore, GLP-1 inhibits glucagon secretion when plasma glucose
concentrations are above normal fasting concentrations while GIP acts glucagonotropically at low
glucose levels. A dual incretin receptor agonist designed to co-activate GLP-1 and GIP receptors was
recently shown to elicit robust improvements of glycemic control (mean haemoglobin A1c reduction
of 1.94%) and massive body weight loss (mean weight loss of 11.3 kg) after 26 weeks of treatment
with the highest dose (15 mg once weekly) in a clinical trial including overweight/obese patients
with type 2 diabetes. Here, we describe the mechanisms by which the two incretins modulate alpha
cell secretion of glucagon, review the effects of co-administration of GLP-1 and GIP on glucagon
secretion, and discuss the potential role of glucagon in the therapeutic effects observed with novel
unimolecular dual GLP-1/GIP receptor agonists. For clinicians and researchers, this manuscript offers
an understanding of incretin physiology and pharmacology, and provides mechanistic insight into
future antidiabetic and obesity treatments.
Keywords: glucagon; glucagon-like peptide 1; glucose-dependent insulinotropic polypeptide; gastric
inhibitory peptide; incretins; dual-agonism; type 2 diabetes; obesity
1. Introduction
The discovery of insulin in the dawn of the 20th century [1] also led to the discovery of a
hyperglycemic substance originating from the pancreas [2]. This substance was named glucagon, short
for glucose agonist, 30 years before it was crystallized and its amino acid sequence was determined [3,4].
Initially, glucagon was exclusively perceived as a hormone opposing the effect of insulin on blood
glucose by stimulating endogenous glucose production, but years of research have paved the way
for a broader understanding of glucagon biology. Today, it is generally accepted that glucagon also
affects regulation of amino acid metabolism [5], while supraphysiological levels of glucagon affect
energy intake and body weight [6,7], energy expenditure [8,9], as well as lipid metabolism [10,11] in
humans. Furthermore, exogenous glucagon has positive chronotropic and inotropic effects on the
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human heart [12–14]. Importantly, hypersecretion of glucagon and ensuing stimulation of endogenous
glucose production plays an important role in the pathophysiology of diabetes contributing to the
hyperglycemia characterizing the diabetic state [15–17]. Glucose, insulin and somatostatin exert
inhibitory effects on alpha cell secretion of glucagon, whereas hypoglycemia and amino acids are
known to stimulate the secretion of glucagon. Also, the gut-derived incretin hormones glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), best known for their potent
insulinotropic effects, modulate glucagon secretion and they may play a role in the dysregulation of
glucagon secretion observed in patients with type 2 diabetes [16]. GLP-1 inhibits glucagon secretion
during hyperglycemia, but not when glucose levels return to euglycemia or during hypoglycemia [18].
As a result, GLP-1 receptor (GLP-1R) agonists (GLP-1RA) reduce hyperglycemia with little risk of
hypoglycemic episodes. In non-diabetics, GIP stimulates glucagon secretion during hypoglycemia
and potentiates insulin secretion during hyperglycemia [19]. The insulinotropic effect of GIP is
severely reduced in patients with type 2 diabetes [20], while the glucagonotropic effect of GIP seems to
prevail [21]. Therefore, GIP receptor (GIPR) agonism has not been pursued in the treatment of type 2
diabetes, but novel GLP-1/GIP receptor agonists may soon redefine the pharmacological role of GIP.
Relevant literature for this review was retrieved from searches in the electronic PubMed database using
the following search terms: “incretin”, “GLP-1”, “GIP”, “glucagon” and “dual agonist”. Furthermore,
manual reference searches in relevant papers and abstracts from scientific meetings were performed.
This review provides insights into the mechanisms by which GLP-1 and GIP modulate glucagon
secretion and discusses findings on glucagon in the context of GLP-1 and GIP co-infusion studies as
well as studies with novel unimolecular dual GIP/GLP-1 receptor agonists.
2. GLP-1 (Glucagon-Like Peptide 1)
2.1. Physiology of GLP-1
Glucagon and the glucagon-like peptides (GLP-1 and glucagon-like peptide 2 (GLP-2)) originate
from tissue specific processing of proglucagon (their common precursor encoded by the glucagon gene)
in the pancreas and the gastrointestinal tract, respectively [22]. Secretion of GLP-1 from intestinal L cells
is meal-related [23] and occurs in response to the presence of nutrients in the lumen of the intestinal
tract [24,25]. Due to the action of the ubiquitous enzyme dipeptidyl peptidase 4 (DPP-4), GLP-1 is
rapidly degraded (T 1
2
1–2 min) to an inactive metabolite [26]. Active GLP-1 interacts with a specific
seven transmembrane G protein-coupled receptor, the GLP-1R, which in humans is known to be
expressed in the pancreas, gastrointestinal tract, kidneys, heart, and the central nervous system [27–30].
Stimulation of the GLP-1R results in activation of adenylate cyclase, which leads to an increase in
cellular concentrations of cyclic adenosine monophosphate (cAMP), activation of protein kinase A
(PKA) and the cAMP-binding protein, Epac [31,32]. There are two isoforms of Epac, Epac1 and
Epac2 [33]. Epac2 is the main isoform present in the pancreas and is involved in GLP-1-mediated
potentiation of glucose-induced insulin secretion [34,35]. The role of Epac1 in the pancreas is less clear,
but it has been suggested to be involved in the maintenance of beta cell mass and the production of
insulin production [36]. As alluded to above, the GLP-1R is widely distributed, and thus, the biological
effects of GLP-1 are manifold. Important physiological effects of GLP-1 include enhancement of
the insulinotropic response of beta cells to intake of nutrients, reduced gastrointestinal secretion
and motility, as well as induction of satiety and ensuing reduction of food intake [37–43]. Sparse
evidence from animal studies suggests that in addition to the well-known effect of GLP-1 on pancreatic
insulin secretion, GLP-1R signaling in the brain may also promote insulin secretion and thereby
glucose tolerance [44,45]. Importantly, GLP-1 is a potent inhibitor of pancreatic glucagon secretion [46].
The glucagonostatic effect of GLP-1 is dependent on the plasma glucose concentration and GLP-1
inhibits glucagon secretion during euglycemia and hyperglycemia but does not affect glucagon
secretion when glucose levels are in the hypoglycemic range (≤3.7 mmol/L) [18]. Blocking the effects of
endogenous GLP-1 using the GLP-1R antagonist exendin (9–39)NH2 in non-diabetic individuals prior
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to ingestion of a carbohydrate-rich drink significantly increases postprandial glucagon secretion [47].
Furthermore, physiological doses of exogenous GLP-1 suppress glucagon secretion in non-diabetic
individuals during a three-step glucose clamp from fasting plasma glucose to plasma glucose levels of 6
and 7 mmol/L respectively, mimicking postprandial glucose excursions [48]. While there is substantial
support for the glucose-dependent glucagonostatic effect of GLP-1, the mechanism(s) by which
GLP-1 inhibits glucagon secretion remains uncertain. At least four hypothesizes have been proposed.
1) The intra-islet hypothesis suggests that GLP-1 mediates glucagon suppression via a paracrine
mechanism. As the beta cell secretory response to high levels of blood glucose is augmented by GLP-1,
so is the paracrine inhibition of glucagon secretion by beta cell secretory products [49]. This hypothesis
also embodies the lack of a glucagonostatic effect of GLP-1 observed during hypoglycemia when GLP-1
has no insulinotropic effect. The fact that GLP-1 strongly inhibits glucagon secretion in individuals
with type 1 diabetes [50–52] nevertheless suggests that other mechanisms are needed to fully account
for the modulatory effect of GLP-1 on glucagon secretion. 2) Another hypothesis behind the inhibitory
effect of GLP-1 on glucagon is through a direct action of GLP-1 on GLP-1R on the alpha cell. This seems
evident in rodents [53], but the presence of the GLP-1R on human alpha cells is a matter of debate.
Reports range from complete lack of the GLP-1R in the human alpha cells [54] to the presence of
a low number of receptors [55,56], which may be enough to mediate the glucagonostatic effects of
GLP-1 [56]. However, specificity issues of commonly used GLP-1R antibodies cast uncertainty upon
these results [57–59]. In a recent study applying an antibody with improved specificity, human alpha
cells were not found to be GLP-1R positive, thus questioning this theory [60]. 3) Neighboring delta
cells were reported to express a high density of GLP-1R when the abovementioned antibody was
applied [60], supporting the theory that GLP-1-mediated glucagon suppression involves the release
of somatostatin from pancreatic delta cells (Figure 1). GLP-1 is a strong mediator of somatostatin
release from delta cells [61–64], and blocking the effects of somatostatin with a somatostatin receptor 2
antagonist diminishes the inhibitory action of GLP-1 in the rat pancreas [61,64]. However, whether
this is also the case in humans remains to be established. 4) Finally, sparse evidence suggests that
part of the modulatory effect of GLP-1 on insulin and glucagon secretion may be mediated by the
parasympathetic nervous system [65–67], but the importance of this mechanism in humans requires
further substantiation.
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Figure 1. Proposed mechanisms of glucose-dependent insulinotropic polypeptide (GIP) and 
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Figure 1. Proposed mecha i l endent insulinotropic polypeptide (GIP) and
glucagon-like peptide 1 (GLP-1) modulation of alpha cell glucagon secretion in humans. AC: adenylate
cyclase, ATP: adenosine triphosphate, cAMP: cyclic adenosine monophosphate, PKA: protein kinase A,
GIPR: GIP receptor, GLP-1R: GLP-1 receptor, SSTR: somatostatin receptor.
Int. J. Mol. Sci. 2019, 20, 4092 4 of 18
Based on a few reports [68,69], the endogenous GLP-1 response to meal ingestion was for years
thought to be reduced in patients with type 2 diabetes. This turned out not to be the case [70,71],
but spurred investigations of exogenous GLP-1 administration in patients with type 2 diabetes.
Interestingly, insulinotropic but not glucagonostatic effects of GLP-1 are significantly reduced in
patients with diabetes [72,73]. However, incretin activity can be observed with administration of
supraphysiological levels of GLP-1RAs [72]. This, combined with the satiety-promoting and food
intake-reducing effects of GLP-1 and its glucose-dependent glucagonostatic effect has paved the way
for the development of GLP-1RAs for the treatment of type 2 diabetes [74].
2.2. GLP-1R (Glucagon-Like Peptide 1 Receptor) Agonism in Type 2 Diabetes
The pharmacological advantages of GLP-1RAs in type 2 diabetes include correction of fasting and
postprandial hyperglycemia (without increased risk of hypoglycemia due to the glucose-dependency of
the insulinotropic and glucagonostatic effects of GLP-1; only operating at plasma glucose levels above
4–5 mmol/L) and weight loss. Furthermore, GLP-1RAs reduce systolic blood pressure (most likely
due to a natriuretic effect of GLP-1 in the kidneys and body weight loss [75]) and postprandial lipids.
Despite the fact that treatment with GLP-1RAs also increases heart rate by 2–8 bpm, cardiovascular
outcomes trials have shown that treatment with some GLP-1RAs (liraglutide, albiglutide, semaglutide,
and dulaglutide) protect against major adverse cardiovascular events in high-risk patients with type 2
diabetes [76]. Additionally, data from these trials also suggest that GLP-1RAs have renoprotective
effects [74,77,78].
The glucagonostatic effect of GLP-1 seems equally important as its insulinotropic action for the
glucose-lowering effect of exogenous GLP-1 in patients with type 2 diabetes [79]. Several clinical trials
have reported that the GLP-1RAs exenatide, liraglutide, dulaglutide and semaglutide decrease fasting
and/or postprandial glucagon secretion [80–84]. However, there are some inconsistencies regarding the
long-term effects of the different GLP-1RAs on glucagon secretion. In the LIBRA trial, initial treatment
with liraglutide decreased glucagon levels [85], but glucagon responses to oral glucose were increased
after 12 weeks of treatment [86]. Furthermore, the AWARD-3 trial reported a significant decrease in
fasting glucagon after 26 weeks of dulaglutide treatment when compared to treatment with metformin,
but no difference between dulaglutide and metformin was observed after 56 weeks [87]. One may
speculate that chronic treatment with GLP-1RAs perhaps decreases alpha cell sensitivity to GLP-1
over time [88]. As a parallel, in vitro studies suggest that rat beta cells are desensitized to GLP-1
during prolonged exposure to GLP-1 [89]. Thus, whereas the glucose-dependent glucagonostatic effect
of GLP-1 is important for its acute glucose-lowering effect, uncertainty remains with respect to the
contribution of this mechanism to the long-term glucose-lowering effect of GLP-1RAs.
3. GIP (Glucose-Dependent Insulinotropic Polypeptide)
3.1. Physiology of GIP
GIP is secreted from intestinal K cells in response to the ingestion of nutrients, especially fat and
carbohydrates [25]. GIP is similarly to GLP-1 inactivated by DPP-4 resulting in a short half-life of
4–7 min [90,91]. The fasting concentrations are usually below 20 pmol/L but may increase to hundreds
of pmol/L in response to a meal dependent on the size of the meal [92]. GIP interacts with the GIPR,
which, like the GLP-1R, is a seven transmembrane G protein-coupled receptor. The main cellular
pathway involved in GIPR signaling involves an increase in intracellular cAMP concentration and
activation of PKA [93,94]. The GIPR is expressed in many tissues including the pancreas, adipose
tissue, gastro-intestinal tract, heart, pituitary gland, adrenal cortex, and the brain [95]. This indicates
pleiotropic functions, and GIP has been suggested to mediate a reduction in bone resorption [96],
increase triacylglyceride deposition in adipose tissue [97] and increase blood flow to the adipose
tissue and intestines [97,98]. Interestingly, GIPR knockout protects against hypothalamic leptin
resistance in diet-induced obese mice [99]. This suggests obesity-promoting effects of naturally
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occurring GIP, but contrasting studies have questioned this view [100]. In non-diabetic individuals,
GIP potentiates postprandial insulin secretion, but this effect is severely diminished or even absent
in people with type 2 diabetes [20,72,101]. Similarly to GLP-1, the insulinotropic effect of GIP is
glucose-dependent, i.e., the effect is absent at plasma glucose less than 4–5 mmol/L [19,102]. Interestingly,
GIP acts glucagonotropically when administered at euglycemia or hypoglycemia [19] but not during
hyperglycemia [19,48]. Due to these inverse glucose-dependent actions on insulin and glucagon
secretion, GIP has been suggested to act as a physiological bifunctional stabilizer of blood glucose [19].
For years, the lack of a suitable GIPR antagonist has limited the study of the physiological effects of
endogenous GIP. But recently a naturally occurring GIP fragment (GIP(3–30)NH2) has been validated
as a GIPR antagonist in humans and used to delineate the effects of endogenous GIP in humans [103].
Using GIP(3–30)NH2 and the GLP-1R antagonist exendin (9–39)NH2, alone and combined, it was
shown in healthy individuals that the plasma glucose-lowering effects of endogenous GIP and GLP-1
after meal ingestion are additive and that endogenous GIP has a greater effect on postprandial glucose
excursions than endogenous GLP-1. Interestingly, it was also shown that the natural suppression
of glucagon secretion occurring after an OGTT was significantly attenuated by exendin(9–39)NH2,
but remained unaffected by GIP(3–30)NH2. Thus, GIP potentiated insulin secretion with no effect on
glucagon secretion in a postprandial setting with hyperglycemia (plasma glucose ~5 to ~10 mmol/L).
Our group recently infused GIP(3–30)NH2 during a liquid meal test in 10 patients with type 2
diabetes [101]. Here, the insulinotropic effect of endogenous GIP was found to be modest, while
glucagon levels were unaffected by the antagonist. These observations are in line with the bifunctional
role of GIP on insulin and glucagon secretion in non-diabetics and the notion of defective potentiation
of insulin secretion by GIP in patients with type 2 diabetes. The role of endogenous GIP in the fasting
state remains to be investigated, and hopefully future studies applying GIP(3–30)NH2 will expand our
knowledge of the role of GIP in normal physiology and in the pathophysiology of type 2 diabetes.
In rodents, the molecular basis for the glucagonotropic action of GIP on alpha cells has been
shown to closely resemble the mechanism of GIP on beta cells, i.e., via an increase in intracellular
cAMP concentration and activation of PKA (Figure 1) [104]. Studies in the perfused rat pancreas have
confirmed that GIP stimulates glucagon secretion directly, while GLP-1 inhibits glucagon secretion in a
somatostatin-dependent paracrine mechanism [61]. Human alpha cells have been found to express the
GIPR [21]. Upon stimulation with GIP, both cAMP generation and glucagon secretion increased in a
concentration-dependent manner which is supportive of a direct action of GIP on alpha cells [21].
3.2. GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor) Agonism in Type 2 Diabetes
Contrary to GLP-1RAs, selective GIPR agonists (GIPRAs) are not available for the treatment of
type 2 diabetes. While the secretion of GIP in patients with type 2 diabetes appears to be normal [105],
the insulinotropic ability of GIP is severely reduced at both physiological [106] and pharmacological
concentrations in these patients [20,72,107]. The diminished insulinotropic effect of GIP may to be
due to glucose-induced downregulation of the GIPR [108] and strict glycemic control has been shown
to partly restore the beta cell sensitivity to GIP [20,106]. The reduced insulinotropic effect of GIP is
considered an important pathophysiological component of type 2 diabetes, which, so far, has rendered
the pursuit of GIP monotherapy as anti-diabetic strategy unattractive. Regarding the modulation of
glucagon secretion by GIP in type 2 diabetes, some studies have found that in patients with type 2
diabetes, the glucagonotropic action of GIP prevails even during hyperglycemia [21,109]. This may
have detrimental effects on postprandial glucose tolerance as exogenous GIP infusion increased
postprandial plasma glucose concentrations in type 2 diabetes patients [21]. Observations made by
our group during clamping of plasma glucose at different glycemic levels, seem to indicate that the
glucagonotropic action of GIP in type 2 diabetes is preserved during periods of hypoglycemia and/or
euglycemia [110]. Based on these short-term clinical experiments the prospect of using GIP as an
antidiabetic agent seems poor, but the long-term effects of GIPR agonism remains to be investigated.
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4. GLP-1 and GIP Dual Agonism
4.1. In Vitro Studies with GLP-1 and GIP in Combination
In insulinoma cells, co-administration of GIP and GLP-1 has been shown to elicit an additive cAMP
response [111]. In line with this, stimulation of rodent beta cells with a combination of GLP-1 and GIP
led to greater potentiation of subsequent glucose or GLP-1-induced insulin secretion than stimulation
with either peptide alone [89]. In human islets from non-diabetic donors and donors with type 2
diabetes, acute exposure to GIP has been reported to be superior to acute exposure with equimolar
amounts of GLP-1 in terms of insulin release [112]. After prolonged exposure, the combination
of both incretins had synergistic effects on insulin synthesis, insulin secretion, and expression of
genes associated with beta cell differentiation and survival than incubation with only one of the two
peptides [112].
4.2. Animal Studies with GLP-1 and GIP Co-infusions
Results from animal studies on the potential additive glucose-regulatory effect of GLP-1 and
GIP are not consistent. Some studies have observed synergistic effects of dual GLP-1R and GIPR
agonism on glucose tolerance, insulin secretion, body weight and food intake in mice [113–115]; others
have found no additional benefits of dual agonism on these parameters compared to treatment with
only one incretin hormone [116]. To our knowledge, glucagon levels have not been reported in these
studies. One study examining mice with diet-induced obesity during co-infusions of a GIPRA and
a GLP-1RA for 14 days found that co-administration did not potentiate the glucose-lowering effects
of either peptide infused alone [117]. However, co-administration augmented reductions in food
intake, body weight and fat mass, and this was the rationale for the development of a unimolecular
dual incretin receptor agonists (i.e., a single molecular structure with agonistic properties both at the
GLP-1R and the GIPR) for the treatment of type 2 diabetes and obesity (this study will be discussed in
more details below) [117]. Glucagon levels were not measured. In line with this, it has been shown
that co-administration of liraglutide and a novel GIPRA leads to a greater reduction in energy intake
and body weight in mice with diet-induced obesity compared to liraglutide alone [118]. Surprisingly,
antagonizing the GIPR protected against body weight gain in mice with diet-induced obesity and led
to a reduced food intake and resting expiratory exchange rate [119]. These results were replicated
in non-human primates with an even more pronounced weight loss [119]. Finally, the combination
of GIPR antagonism and a GLP-1RA enhanced the observed weight loss in all animal models [119].
Although GLP-1 and GIP co-administration has almost consistently demonstrated positive effects on
body weight, it is paradoxical that both GIPR agonism and antagonism seem to enhance the effects
of GLP-1R agonism. This highlights that the mechanisms mediating any additive effect of GIP and
GLP-1 in terms of body weight reduction are not well-described; and particularly the role of glucagon
in these preclinical findings remain obscure.
4.3. Human Studies with GLP-1 and GIP Co-infusions
The effects of short-term GLP-1 and GIP co-infusion have been investigated in both non-diabetic
individuals and patients with type 2 diabetes. The separate and combined effects of GLP-1 and
GIP were investigated by Nauck et al. in 8 non-diabetic subjects during intravenous isoglycemic
glucose infusions (IIGI) mimicking a preceding OGTT [120]. The infusion rates of GIP and GLP-1
(1 and 0.3 pmol/kg/min, respectively) were chosen to reach plasma concentrations identical to the
concentrations of the endogenous hormones during the OGTT. The combined effects of the incretins
were greater than the separate effects in terms of insulin secretion, but infusion of GLP-1 and/or GIP
had no additional effect on glucagon secretion compared to the IIGI [120]. Elahi et al. examined the
separate and combined effects of GLP-1 and porcine GIP in 6–7 non-diabetic individuals during a
hyperglycemic clamp (5.4 mmol/L above fasting plasma glucose) [121]. The infusion rates were 1.5
and 2 pmol/kg/min for GLP-1 and GIP, respectively. The co-infusion significantly inhibited glucagon
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secretion and potentiated insulin secretion. These effects were superior compared to infusion of
either peptide alone [121]. Daousi et al. investigated the effects of mono-infusions and co-infusion
of GLP-1 (1 pmol/kg/min) and GIP (2 pmol/kg/min) during a 4-h intravenous glucose infusion in 6
non-diabetic men and 6 men with type 2 diabetes [122]. In the non-diabetic men, the co-infusion
significantly increased insulin response to glucose compared to mono-infusion of either hormone
alone. This was not the case in the patients with type 2 diabetes, which is in line with the generally
reduced insulinotropic effect of GIP in individuals with type 2 diabetes as previously described.
Unfortunately, glucagon responses were not reported in this study. Nevertheless, scrutinizing the
plasma glucose excursions, it may seem that GIP alone had a moderate hyperglycemic effect in both
groups. Furthermore, co-administration of GLP-1 and GIP resulted in glucose excursions identical to
those observed with mono-infusion of GLP-1 despite a numerically greater insulin response during
co-infusion. One may speculate that GIP-mediated glucagon secretion underlies this phenomenon.
Our group has studied the separate and combined effects of GIP, GLP-1 and GLP-2 (the latter known
to be glucagonotropic but without any notable effect on insulin secretion [123]) on glucagon secretion
in 10 patients with type 2 diabetes [109]. After an initial OGTT, the participants completed four IIGIs
with infusions of either GIP (4 pmol/kg/min), GLP-1 (0.6 pmol/kg/min), GLP-2 (1 pmol/kg/min) or
the combination of all three peptides. The infusion rates were chosen to mimic physiological plasma
concentrations of the peptides in the portal circulation. While GLP-1 suppressed glucagon secretion
and GIP promoted the release of glucagon, we observed no changes in glucagon secretion during
co-infusion, suggesting that the bidirectional effects of GLP-1 and GIP/GLP-2 on glucagon secretion
nullify each other. Furthermore, insulin secretion was equally potentiated by infusion of GLP-1 alone
or in combination with GIP (and GLP-2), but not GIP alone, confirming the reduced insulinotropic
effect of GIP in these patients. These findings were confirmed when Mentis et al. investigated whether
GIP could potentiate the insulinotropic or glucagonostatic effects of GLP-1 in type 2 diabetes without
concomitant glucose infusion [107]. After an overnight fast, 12 patients with type 2 diabetes received
infusions of GIP (4 pmol/kg/min), GLP-1 (1.2 pmol/kg/min) or the combination of both for 6 h. In this
setting, GIP did not enhance the insulin response to GLP-1 during co-infusion, which also resulted
in blood glucose levels equal to infusion of GLP-1 alone. Furthermore, GLP-1-induced inhibition
of glucagon secretion was reduced during co-infusion [107]. Recently, our group investigated the
effects of combined GIP and GLP-1 infusion in seventeen overweight/obese individuals during 4
different IIGIs (mimicking a preceding OGTT) with co-infusion of either saline, GIP (4 pmol/kg/min),
GLP-1 (1 pmol/kg/min) or GIP + GLP-1 (4 and 1 pmol/kg/min, respectively) [124]. Compared to IIGI +
saline, IIGI + GLP-1 suppressed glucagon secretion, whereas the glucagonotropic response during
IIGI + GIP + GLP-1 did not differ from IIGI + saline, suggesting opposing actions of GLP-1 and
GIP on glucagon secretion in these non-diabetic overweight/obese men. The insulin response was
similar during infusions of GLP-1 and GLP-1 + GIP and far greater than during infusion of GIP alone.
This may imply that overweight/obese men, similarly to patients with type 2 diabetes, have reduced
beta cell sensitivity to GIP. In fact, this study was designed to evaluate the effect of GIP—alone and in
combination with GLP-1—on ad libitum meal intake; only the infusion of GLP-1 alone resulted in a
significant decrease in energy intake compared to saline. Unpublished data from our group (Bergmann
et al., unpublished) suggest that individuals with type 2 diabetes who are treated with a long-acting
GLP-1RA have no additional benefit of high-dose exogenous GIP. Twenty-two patients (all treated
with metformin and a long-acting GLP-1RA) received 5-h infusions of GIP (6 pmol/kg/min) or saline.
Initially, a standardized liquid mixed meal test was performed, and an ad libitum meal was served at
the end of the infusion for evaluation of energy intake. GIP had no influence on energy intake, appetite,
energy expenditure, gastric emptying, gallbladder motility or plasma lipids compared to placebo.
However, glucagon secretion was augmented during GIP infusion and plasma glucose excursions
were significantly greater compared to a placebo.
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4.4. Unimolecular Dual GLP-1 and GIP Receptor Agonists
After the demonstration of the synergistic effects of GLP-1 and GIP co-administration in mice,
a series of peptides with balanced agonism at both the GLP-1R and GIPR was derived from a
glucagon-core [117]. One such unimolecular dual-agonist, RG7697, was found to display balanced and
potent activity at GIPR and GLP-1R and minimal activity at the glucagon receptor in vitro. RG7697 is
believed to bind to only one receptor at a time, resulting in less GLP-1R occupancy at equimolar doses
to those of selective GLP-1RAs and ultimately fewer gastrointestinal side effects, which is considered
the dose-limiting step of the GLP-1RAs. It is still not clear to which degree GLP-1R and GIPR activation,
respectively, contribute to the activity of unimolecular dual agonists and in vivo potency of dual
agonists at the incretin receptors remains to be determined. At any rate, when administered at
equimolar doses to diet-induced obese mice, RG7697 led to a greater weight loss while demonstrating
superior insulinotropic and antihyperglycemic effects after a glucose challenge compared to selective
GLP-1RAs in db/db mice, lean rats, Zucker diabetic fatty rats, and cynomolgus monkeys [117]. No
glucagon data were published from this study.
In 18 non-diabetic humans, RG7697 was infused during a glucose infusion with positive effects on
glucose control paralleled by an increased glucose-induced insulin response [117]. However, there
was no direct comparison with a GLP-1RA. Furthermore, in 44 patients with type 2 diabetes, RG7697
dose-dependently reduced HbA1c during six weeks of treatment but, again, no comparison was made
to a selective GLP-1RA [117]. To our knowledge, no glucagon measurements have been reported from
either of these human studies.
In another study, the effects of ascending doses of RG7697 administered subcutaneously to
38 non-diabetic subjects over 96 h were evaluated [125]. Assessed by a meal tolerance test after
treatment, RG7697 dose-dependently reduced maximal plasma glucose and insulin concentrations
by up to ~50% compared to a meal tolerance test at baseline [125]. This was not accompanied by any
changes in postprandial glucagon levels even at the highest dosing. With no comparison to a selective
GLP-1R, it is not clear if the benefits of dual-agonism observed here surpassed those of pharmacological
GLP-1R activation alone.
In two cohorts of ~40 patients with type 2 diabetes, RG7697 reduced fasting, postprandial and 24-h
glucose levels as well as HbA1c dose-dependently [126,127]. Postprandial insulin levels decreased after
treatment with RG7697 while postprandial glucagon levels were reported to be slightly reduced [126]
or not reported at all [127]. Treatment with RG7697 was also associated with weight loss, but this was
comparable to the weight loss observed with placebo treatment [126,127]. RG7697 was not directly
compared with a selective GLP-1RA so whether RG7697′s GIPR-stimulating effect contributes to the
abovementioned effects remains unclear.
A novel dual GIPR/GLP-1R agonist, tirzepatide (also known as LY3298176), has been developed
for once-weekly administration [128]. In vitro, the affinity of tirzepatide is comparable to natural GIP
for the GIPR and ~5-fold weaker than natural GLP-1 for the GLP-1R. Additionally, tirzepatide potently
stimulates cAMP accumulation in recombinant cell lines expressing the GIPR or the GLP-1R, but has
minimal activity on the glucagon receptor [128]. In mice, glucose tolerance after intraperitoneal glucose
infusion was improved by tirzepatide [128]. Compared to a selective GLP-1RA, tirzepatide provided
better weight loss and a superior reduction in food intake with increased energy expenditure in mice
with diet-induced obesity [128]. Glucose excursions during OGTT were decreased dose-dependently
with tirzepatide and also significantly decreased with dulaglutide, and insulin levels during OGTT were
similar after treatment with either compound [128]. Glucagon levels during OGTT were not reported.
Ascending doses of tirzepatide (0.5–15 mg once-weekly) over 4 weeks was compared to placebo
in 25 normal glucose tolerant subjects and 42 patients with type 2 diabetes [128]. The GLP-1RA
dulaglutide (1.5 mg once-weekly) was administered to a small group of 4 non-diabetic individuals as a
control. Tirzepatide dose-dependently reduced fasting glucose but not fasting insulin in non-diabetic
individuals. Oral glucose tolerance was significantly improved across all doses of tirzepatide and
dulaglutide but with no effect on insulin responses to OGTTs. Subjects receiving the highest dosing of
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tirzepatide reduced body weight by ~4 kg after 4 weeks of treatment [128]. In patients with type 2
diabetes, tirzepatide was shown to reduce fasting glucose and insulin levels dose-dependently [128].
Oral glucose tolerance was significantly improved and accompanied by enhanced OGTT-induced
insulin secretion. A dose and time-dependent weight loss was also observed, although with a smaller
effect size when compared to the non-diabetic subjects. To our knowledge, no glucagon outcomes have
been reported from this trial. The efficacy of tirzepatide was later evaluated in a larger group of patients
with type 2 diabetes (n = 316) [129]. Participants were randomly assigned to receive either tirzepatide
(1, 5, 10 or 15 mg), dulaglutide (1.5 mg — currently the highest recommended dose) or placebo for
26 weeks (~50 participants in each group). To help improve tolerability, patients assigned to the 10 mg
group received 5 mg for 2 weeks and 10 mg for the rest of the study. Patients assigned to the 15 mg
group received 5 mg for 2 weeks, then 10 mg for two weeks and 15 mg for the remaining duration of
the study. At 26 weeks, tirzepatide decreased HbA1c dose-dependently and without plateau (−1.06,
−1.75, −1.89 and −1.94% for 1, 5, 10 and 15 mg, respectively) [129]. The reduction in HbA1c by
dulaglutide was −1.21%. Body weight was reduced with tirzepatide (−0.9, −4.8, −8.7 and −11.3 kg
for 1, 5, 10 and 15 mg, respectively) compared to a −2.7 kg reduction in weight by dulaglutide [129].
Tirzepatide, like dulaglutide, reduced fasting and postprandial plasma glucose. Interestingly, fasting
glucagon decreased dose-dependently with tirzepatide, while fasting insulin decreased at all doses
above 1 mg [129]. Dulaglutide (1.5 mg) reduced fasting glucagon and increased fasting insulin in a
manner comparable to 1 mg tirzepatide. At the highest dosing, tirzepatide surpassed dulaglutide in
number of adverse events, especially gastrointestinal adverse events (66.0% of individuals treated with
tirzepatide 15 mg and 42.6% of individuals treated with dulaglutide 1.5 mg), but also in total number
of hypoglycemic episodes (7.5% of participants receiving 15 mg tirzepatide versus 3.7% of participants
receiving dulaglutide) [129]. To circumvent this issue, an adverse event-lowering titration strategy
for tirzepatide has been reported [130]. However, the alternative three-step dose escalation regimen
for 15 mg tirzepatide did not seem to effectively lower the overall incidence of gastrointestinal side
effects compared to the previously reported study [129]. The incidence of hypoglycemic episodes also
increased to ~16% of participants receiving 15 mg tirzepatide. Although tirzepatide treatment was still
associated with a promising weight loss (~5.6 kg after 12 weeks), the high rate of gastrointestinal side
effects did cast some uncertainty upon the clinical potential of tirzepatide. From a mechanistic point of
view, it is interesting to note that tirzepatide has been shown to delay gastric emptying in a manner
similar to the selective GLP-1RA semaglutide with tachyphylaxis after prolonged treatment [131].
Furthermore, tirzepatide was also found to regulate human adipocytes via GIPR specific activity,
perhaps providing some of the mechanistic basis for its pharmacological body weight-lowering
effect [132]. Taken together, the abovementioned trials suggest that dual incretin receptor agonists may
constitute effective HbA1c-lowering and body weight-reducing agents in patients with type 2 diabetes.
But these effects need to be considered in light of the frequent gastrointestinal adverse events at the
most efficacious doses.
Whether some of the effects of dual incretin receptor agonism are mediated via glucagon remains
mostly unknown. Many of the aforementioned studies did not report any glucagon outcomes, but some
trials found a decrease in postprandial [126] or fasting [129] plasma glucagon concentrations, while
others reported no changes in postprandial glucagon secretion following dual incretin receptor agonist
treatment [125]. One study found that in patients with type 2 diabetes, tirzepatide decreased glucagon
concentrations despite concomitant lowering of plasma glucose, much like a GLP-1RA, but with greater
magnitude [129]. This is surprising, given that the GIP component of tirzepatide is glucagonotropic
in patients with type 2 diabetes as would be expected from co-infusion studies with GIP and GLP-1.
This raises questions regarding the effect of GIPR activation in addition to chronic GLP-1R agonism:
Is the GIP component active in humans or is it the effect of potent GLP-1R activation that is observed?
And if it is active, what is the contribution of the GIP component to the mode of action of these
drugs? Interestingly, when comparing the effects of 1.5 [128] or 1 mg tirzepatide [129] on body weight
and glycaemia with the effects of 1.5 mg dulaglutide, they were more or less identical, but with
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fewer gastrointestinal adverse effects. Furthermore, the relatively high incidence of hypoglycemic
episodes may suggest that the GIP component is not active and therefore does not protect against
hypoglycemia. It is difficult to delineate the individual contribution of the GLP-1 and GIP components
to the effects of the dual agonists. Comparing these drugs to long-acting selective GLP-1 and GIP
agonists separately would help define the contribution of each incretin component to the effects
of unimolecular dual-agonism. In any case, the dual incretin receptor agonists appear to be better
tolerated than their selective GLP-1R agonistic counterparts at equimolar doses, which may allow for
higher dosing than with GLP-1RAs. Whether the apparently enhanced tolerability is due to the GIP
component or other factors remains to be determined. Glucagon, with its pleiotropic functions on
hepatic glucose production, energy homeostasis and body weight, is arguably an important endocrine
factor to consider when delineating the effects of dual GLP-1R/GIPR agonism. Given that GLP-1 is
a potent inhibitor of glucagon in patients with type 2 diabetes [109], it not surprising that glucagon
concentrations seem to diminish following dual incretin receptor agonist treatment—although this
observation is far from consistent and supported by only two studies [126,129]. However, considering
that GIP acts glucagonotropically in patients with type 2 diabetes [21,109] the GIP component of dual
incretin receptor agonists might counteract GLP-1-mediated inhibition of glucagon secretion, leading
to a neutral effect on glucagon levels. Indeed, one study found that postprandial glucagon levels were
unaffected by short-term treatment with a dual incretin receptor agonist [125]. These are speculative
interpretations and future studies are needed to delineate the role of glucagon in the mode of action of
this emerging treatment strategy for obesity and type 2 diabetes.
5. Conclusions and Perspectives
Recent studies have demonstrated beneficial effects on glycemic control and body weight with
dual GIPR/GLP-1R agonists. Hyperglucagonemia is a common phenomenon in type 2 diabetes
and—via glucagon’s stimulatory effect on endogenous glucose production—it contributes to the core
pathophysiological trait of these patients namely hyperglycemia. Also, glucagon seems to regulate
energy homeostasis and body weight. As both incretin hormones are known to modulate glucagon
secretion (in opposite ways and at different glucose levels), pharmacological dual incretin receptor
agonism may have effects on glucagon secretion that are of clinical importance.
It is difficult to disentangle the individual effects of GLP-1R and GIPR activation by the emerging
unimolecular dual incretin receptor agonist compounds. The possibility exists that dual incretin
receptor agonists simply work by potent activation of the GLP-1R; with any GIPR activity being
clinically unimportant. At equimolar doses, the unimolecular dual incretin receptor agonist tirzepatide
has effects that are strikingly comparable to dulaglutide. The individual contribution of the GIPR
and GLP-1R to the pharmacological effects of long-term dual incretin receptor agonism could be
determined by individual and combined administration of selective mono GLP-1R and mono GIPR
antagonists or by comparison with long-term selective GLP-1 and GIP agonists.
Preclinical studies illustrate the paradox that both GIPR agonism and antagonism compliments
GLP-1R activity. It may be speculated that long-term GIPR agonism may result in GIPR downregulation
to such a degree that it effectively becomes universal GIPR antagonism. This could contribute to body
weight loss, since GIP seems to increase blood flow to adipose tissue and facilitate triacylglycerol
deposition in adipocytes. If this applies to dual incretin receptor agonists, antagonizing the GIPR may
compliment the GLP-1R-mediated inhibition of glucagon secretion, which would ultimately lower
endogenous glucose production and plasma glucose.
Interestingly, suppression of glucagon activity by the GLP-1 component of dual incretin receptor
agonists may not be clinically beneficial after all, as studies investigating GLP-1, GIP and glucagon
receptor tri-agonists have shown potential in reducing body weight and hyperglycemia [133–136].
Future studies will need to delineate the role of both glucagon, GLP-1, and GIP in the mode of action
of glucagon and incretin-based drug candidates.
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